Drugs / TYF-CGD-modified autologous stem cells
TYF-CGD-modified autologous stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03645486 | Jul 2025 → Jun 2028 expected | chronic granulomatous disease | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYF-CGD-modified autologous stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03645486 ↗ |
| Action | Restore | “using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene” NCT03645486 ↗ |
| Modality | Cell therapy | “Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene” NCT03645486 ↗ |